Welcome to our dedicated page for Schrodinger news (Ticker: SDGR), a resource for investors and traders seeking the latest updates and insights on Schrodinger stock.
Schrodinger, Inc. (symbol: SDGR) is a top-tier provider of state-of-the-art molecular simulations and enterprise software solutions, catering primarily to the pharmaceutical, biotechnology, and materials science industries. With its pioneering software, Schrodinger empowers scientists to accelerate research and development, cut down on research expenses, and make groundbreaking discoveries that might not be feasible otherwise.
Established in 1990, Schrodinger has continually invested in fundamental research, leading to numerous scientific breakthroughs in drug discovery and materials science. The company's researchers have contributed hundreds of peer-reviewed scientific publications, often cited as significant works in their respective fields.
Schrodinger operates through two main segments: Software and Drug Discovery. The Software segment focuses on selling advanced software that revolutionizes drug discovery across the life sciences industry. It also caters to customers in materials science. The Drug Discovery segment generates revenue from a portfolio of preclinical and clinical programs, both internally developed and through collaborations.
Schrodinger has established profound partnerships and collaborations with companies in biotechnology, pharmaceuticals, chemicals, and electronics. One notable collaboration is with Nimbus Therapeutics, a biotech firm co-founded by Schrodinger. The company's global presence includes operations in the U.S., Europe, Japan, and India.
Recent achievements highlight Schrodinger's continuous innovation and success. The predictive power of its software solutions has led to significant advancements in scientific research, enhancing the efficiency and efficacy of drug discovery processes. Schrodinger's commitment to excellence and scientific integrity ensures it remains at the forefront of its industry, driving forward the boundaries of what is possible in molecular simulations and drug discovery.
Schrödinger, Inc. (Nasdaq: SDGR) announced the grant of non-statutory stock options for 45,050 shares to 15 newly hired employees on
Schrödinger (Nasdaq: SDGR) has announced its participation in four investor conferences in September 2021. On September 9 at 2:00 p.m. ET, the company will present at the Morgan Stanley 19th Annual Global Healthcare Conference. A pre-recorded presentation will be available on September 13. Additionally, Schrödinger will participate in the BofA Global Healthcare Conference on September 16 and the BofA Securities Drug Discovery Conference on September 20. Live webcasts can be accessed on their website and will be archived for about seven days.
Schrödinger, Inc. (Nasdaq: SDGR) recently granted stock options to 13 new employees, totaling 25,150 shares under its 2021 Inducement Equity Incentive Plan. The options, priced at $57.40 per share, were approved by the compensation committee and are intended to attract talent. Each option has a 10-year term, vesting over four years. Schrödinger's innovative software platform advances drug development and material science, serving clients globally to accelerate the discovery of novel therapeutics.
Schrödinger (Nasdaq: SDGR) announced a 29% increase in Q2 2021 revenue to $29.8 million, with software revenue rising 15% to $24.1 million. The company reported a gross profit of $12 million, though overall operating expenses grew to $42.3 million, leading to a net loss of $34.6 million. Notably, Schrödinger has partnered with Zai Lab to co-develop an oncology program, and expects to submit up to three IND applications in 2022. The company anticipates full-year revenue between $124 million and $142 million. Cash and equivalents totaled $616.6 million as of June 30, 2021.
Schrödinger (Nasdaq: SDGR) and Zai Lab (Nasdaq: ZLAB; HKEX: 9688) have announced a collaboration to jointly discover, develop, and commercialize a novel oncology program targeting DNA damage response. Zai Lab will initially fund Schrödinger's research costs and lead global development post candidate selection. Schrödinger retains co-development rights in the U.S. and can earn up to $338 million in milestone payments, plus royalties on international sales. This partnership aims to leverage both companies' expertise to accelerate innovative cancer therapies.
Schrödinger (Nasdaq: SDGR) is set to host a conference call on August 12, 2021, at 8:30 a.m. ET to discuss its Q2 2021 financial results and provide a business update. The event will be accessible via webcast on their investor site. Schrödinger is known for its innovative physics-based software platform that facilitates the rapid discovery of novel therapeutics and materials, significantly reducing costs compared to traditional methods. The company collaborates with various sectors globally, leveraging its technology to enhance drug development.
Schrödinger, Inc. (Nasdaq: SDGR) is hosting its first annual Educator's Day, aimed at enhancing the role of computational tools in education. The event features discussions on the development of curricula for teaching chemical interactions and drug design using Schrödinger's software. Keynote speaker Dr. Brent R. Stockwell emphasizes the importance of modern curricula for today’s scientists. Schrödinger aims to fill the resource gap in hands-on learning by training educators and facilitating effective learning through innovative methods.
Schrödinger (Nasdaq: SDGR) announced the granting of stock options to 14 new employees on July 15, 2021, totaling 32,975 shares. These options, part of the 2021 Inducement Equity Incentive Plan, have an exercise price of $67.46, matching the closing stock price on the grant date. The options vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years. This initiative aims to attract talent and is compliant with Nasdaq Listing Rule 5635(c)(4).
Schrödinger (Nasdaq: SDGR) is set to present at two investor conferences in July 2021. The first presentation will occur on July 20, 2021, at the Evercore ISI AI x Therapeutics Day at 1:30 PM ET. The second presentation is scheduled for July 28, 2021, at the SVB Leerink CybeRx Conference at 2:00 PM ET. Schrödinger's innovative physics-based software platform enhances the discovery of therapeutics and materials, allowing for faster and cost-effective development.
Schrödinger, Inc. (Nasdaq: SDGR) announced on June 13, 2021, the grant of non-statutory stock options for 32,850 shares to 14 new employees. This action, part of the 2021 Inducement Equity Incentive Plan, was aimed at encouraging the employees to join the company. Each option has an exercise price of $77.51, equal to the stock's closing price on June 11, 2021. The options vest over four years, with a portion vesting after the first year and the remainder in monthly installments thereafter. Schrödinger continues to leverage its software platform for innovative drug and materials discovery.
FAQ
What is the current stock price of Schrodinger (SDGR)?
What is the market cap of Schrodinger (SDGR)?
What does Schrodinger, Inc. do?
When was Schrodinger, Inc. founded?
What are the main segments of Schrodinger’s business?
How does Schrodinger generate revenue?
What industries does Schrodinger’s software cater to?
What are some of Schrodinger’s recent achievements?
Where are Schrodinger’s operations located?
What is Nimbus Therapeutics?
How has Schrodinger contributed to scientific research?
What makes Schrodinger's software unique?
